Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081479 | 0.78 | — | — | |
| SCHEMBL28181670 | 0.77 | AOC3 (0.48) | AOC3ALDH1A1KCNH2CA12CA1 | |
| SCHEMBL26647420 | 0.75 | AOC3 (0.52) | AOC3ALDH1A1CA12CA1CA2 | |
| SCHEMBL27809890 | 0.72 | ALOX15 (0.42) | ALDH1A1ENPP1KDM4E | |
| SCHEMBL5202073 | 0.72 | L3MBTL1 (0.43) | ALDH1A1L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL2059142 | 0.72 | AOC3 (0.47) | AOC3ALDH1A1L3MBTL1 | |
| SCHEMBL2148701 | 0.71 | ALDH1A1 (0.39) | AOC3ALDH1A1ENPP1L3MBTL1HPGD | |
| SCHEMBL22339621 | 0.71 | CYP17A1 (0.36) | AOC3ALDH1A1KCNH2L3MBTL1HPGD | |
| SCHEMBL907670 | 0.71 | KDM4E (0.43) | ALDH1A1HPGDKDM4E | |
| SCHEMBL8128943 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (NL) | 2018-03-29 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-0735024-A1 | Antidepressant N-(Heteroarylaminoalkyl)-4-napthyl substituted piperidines and tetrahydroperidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5472966-A | Antiserotonin agents; side effect reduction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0464558-B1 | Antimigraine alkoxypyrimidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0464558-A1 | Antimigraine alkoxypyrimidine derivatives | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | AOC3 1346/4885ALDH1A1 56/4885ENPP1 1172/4885 |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | AOC3 2328/4885ALDH1A1 4285/4885ENPP1 2585/4885 |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | AOC3 2328/4885ALDH1A1 4285/4885ENPP1 2585/4885 |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | AOC3 2328/4885ALDH1A1 4285/4885ENPP1 2585/4885 |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | AOC3 2328/4885ALDH1A1 4285/4885ENPP1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.